Engitix Ltd., a U.K.-based biopharmaceutical company whose backers include billionaire hedge fund manager Michael Platt, has raised $54 million in private financing to boost growth.
The series A funding round was co-led by existing backer Netherton Investments, a fund allocating on behalf of Platt, and new investor Dompe Farmaceutici SpA, according to a statement obtained by Bloomberg News.
